CoChat
Sign Up
Cited by 268

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

The germinal centre B cell response to SARS-CoV-2

Laidlaw, Brian J., Ellebedy, Ali H.·2022·Nature Reviews Immunology
DOI 10.1038/s41577-021-00657-1PMC PMC8647067
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41577-021-00657-1

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 62 references

Research works printed but not linked: 128

  1. Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524–540 (2019). · DOI
  2. Victora, G. D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592–605 (2010). · DOI
  3. Gitlin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509, 637–640 (2014). · DOI
  4. Gitlin, A. D. et al. T cell help controls the speed of the cell cycle in germinal center B cells. Science 349, 643–646 (2015). · DOI
  5. Kräutler, N. J. et al. Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells. J. Exp. Med. 214, 1259–1267 (2017). · DOI
  6. Allen, C. D. C., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190–202 (2007). · DOI
  7. Weisel, F. J., Zuccarino-Catania, G. V., Chikina, M. & Shlomchik, M. J. A temporal switch in the germinal center determines differential output of memory b and plasma cells. Immunity 44, 116–130 (2016). · DOI · Paper page
  8. Shinnakasu, R. et al. Regulated selection of germinal-center cells into the memory B cell compartment. Nat. Immunol. 17, 861–869 (2016). · DOI
  9. Laidlaw, B. J., Duan, L., Xu, Y., Vazquez, S. E. & Cyster, J. G. The transcription factor Hhex cooperates with the corepressor Tle3 to promote memory B cell development. Nat. Immunol. 21, 1082–1093 (2020). · DOI
  10. Crotty, S. et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969–4973 (2003). · DOI · Paper page
  11. Zuccarino-Catania, G. V. et al. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat. Immunol. 15, 631–637 (2014). · DOI
  12. McCarthy, K. R. et al. Memory B Cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires. Immunity 48, 174–183.e9 (2018). · DOI
  13. Williams, L. D. et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol. 2, eaal2200 (2017). · DOI
  14. Zehentmeier, S. et al. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. Eur. J. Immunol. 44, 2306–2317 (2014). · DOI
  15. Brynjolfsson, S. F., Mohaddes, M., Kärrholm, J. & Wick, M.-J. Long-lived plasma cells in human bone marrow can be either CD19+ or CD19–. Blood Adv. 1, 835–838 (2017). · DOI
  16. Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K. & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 397, 1204–1212 (2021). · DOI · Paper page
  17. Santos, L. A. D. et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J. Infect. 82, 399–406 (2021). · DOI
  18. Kiyuka, P. K. et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J. Infect. Dis. 217, 1728–1739 (2018). · DOI
  19. Monto, A. S. et al. Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J. Infect. Dis. 222, 9–16 (2020). · DOI
  20. Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681 (2021). · DOI · Paper page
  21. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021). · DOI · Paper page
  22. Anand, P. & Stahel, V. P. The safety of Covid-19 mRNA vaccines: a review. Patient Saf. Surg. 15, 20 (2021).
  23. Tang, L. et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 325, 2500–2502 (2021). · DOI
  24. Angel, Y. et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA 325, 2457–2465 (2021). · DOI
  25. Regev-Yochay, G. et al. Decreased infectivity following BNT162b2 vaccination. SSRN Electron J. https://doi.org/10.2139/ssrn.3815668 (2021). · DOI
  26. Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421–425 (2021). · DOI
  27. Ripperger, T. J. et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low prevalence communities and reveal durable humoral immunity. Immunity 53, 925–933.e4 (2020). · DOI
  28. Muecksch, F. et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J. Infect. Dis. 223, jiaa659 (2020).
  29. Wang, K. et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin. Infect. Dis. 73, e1143–e1539 (2020).
  30. Chen, Y. et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell 183, 1496–1507.e16 (2020). · DOI
  31. Vaisman-Mentesh, A. et al. SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time. Preprint at medRxiv https://doi.org/10.1101/2020.08.23.20179796 (2020). · DOI
  32. Moriyama, S. et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54, 1841–1852.e4 (2021). · DOI
  33. Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 21, 1506–1516 (2020). · DOI · Paper page
  34. Fenoglio, D. et al. Characterization of T lymphocytes in severe COVID-19 patients. J. Med. Virol. 93, 5608–5613 (2021). · DOI
  35. Adamo, S. et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy 76, 2866–2881 (2021). · DOI
  36. Zhang, J. et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat. Microbiol. 6, 51–58 (2021). · DOI
  37. Nielsen, S. C. A. et al. Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. Cell Host Microbe 28, 516–525.e5 (2020). · DOI
  38. Hoehn, K. B. & Kleinstein, S. H. Cutting edge: distinct B cell repertoires characterize patients with mild and severe COVID-19. J. Immunol. 206, 2785–2790 (2021). · DOI
  39. Chen, Z. & Wherry, E. J. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 20, 529–536 (2020). · DOI · Paper page
  40. Ellebedy, A. H. et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat. Immunol. 17, 1226–1234 (2016). · DOI
  41. Phan, T. G. et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J. Exp. Med. 203, 2419–2424 (2006). · DOI
  42. Lakshmanappa, Y. S. et al. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nat. Commun. 12, 541 (2021).
  43. Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. https://doi.org/10.1126/sciimmunol.abl9105 (2021). · DOI
  44. Dugan, H. L. et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290–1303.e7 (2021). · DOI · Paper page
  45. Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell 184, 1858–1864.e10 (2021). · DOI
  46. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021). · DOI · Paper page
  47. Krishnamurty, A. T. et al. Somatically hypermutated plasmodium-specific IgM+ memory B cells are rapid, plastic, early responders upon malaria rechallenge. Immunity 45, 402–414 (2016). · DOI
  48. Pritchard, G. H. et al. The development of optimally responsive plasmodium-specific CD73+CD80+IgM+ memory B cells requires intrinsic BCL6 expression but not CD4+ Tfh cells. Preprint at bioRxiv https://doi.org/10.1101/564351 (2019). · DOI
  49. Toyama, H. et al. Memory B cells without somatic hypermutation are generated from Bcl6-deficient B cells. Immunity 17, 329–339 (2002). · DOI
  50. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021). · DOI · Paper page
  51. Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.e6 (2021). · DOI · Paper page
  52. Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 184, 4969–4980.e15 (2021). · DOI
  53. DiMuzio, J. M. et al. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine X 8, 100098 (2021). · DOI
  54. Saadat, S. et al. Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. Preprint at medRxiv https://doi.org/10.1101/2021.01.30.21250843 (2021). · DOI
  55. Bradley, T., Grundberg, E. & Selvarangan, R. Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine. Preprint at medRxiv https://doi.org/10.1101/2021.02.03.21251078 (2021). · DOI
  56. Samanovic, M. I. et al. Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. Preprint at medRxiv https://doi.org/10.1101/2021.02.07.21251311 (2021). · DOI
  57. Levi, R. et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19. J. Clin. Invest. https://doi.org/10.1172/jci149154 (2021). · DOI
  58. Lozano-Ojalvo, D. et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals. Cell Rep. 36, 109570 (2021). · DOI
  59. Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981–984 (2021). · DOI
  60. Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021). · DOI · Paper page
  61. Gallagher, K. M. E. et al. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. Preprint at bioRxiv https://doi.org/10.1101/2021.05.03.442455 (2021). · DOI
  62. DiPiazza, A. T. et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 54, 1869–1882.e6 (2021). · DOI
  63. Hoehn, K. B. et al. Human B cell lineages engaged by germinal centers following influenza vaccination are measurably evolving. Preprint at bioRxiv https://doi.org/10.1101/2021.01.06.425648 (2021). · DOI
  64. Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021). · DOI · Paper page
  65. Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans. Preprint at bioRxiv https://doi.org/10.1101/2021.09.08.459485 (2021). · DOI
  66. Kim, W. et al. Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccination. Preprint at bioRxiv https://doi.org/10.1101/2021.10.31.466651 (2021). · DOI
  67. Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565 (2013).
  68. Ferron, F. et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl Acad. Sci. USA 115, E162–E171 (2018). · DOI
  69. Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020). · DOI · Paper page
  70. Jangra, S. et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. Preprint at medRxiv https://doi.org/10.1101/2021.01.26.21250543 (2021). · DOI
  71. Nonaka, C. K. V. et al. Genomic evidence of a SARS-CoV-2 reinfection case with E484K spike mutation in Brazil. Emerg. Infect. Dis. 596, 1522–1524 (2021). · DOI
  72. Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Preprint at bioRxiv https://doi.org/10.1101/2021.01.25.427948 (2021). · DOI · Paper page
  73. Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4236.e13 (2021). · DOI · Paper page
  74. Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331–2333 (2021). · DOI · Paper page
  75. Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature https://doi.org/10.1038/s41586-021-04085-y (2021). · DOI · Paper page
  76. Cho, A. et al. Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination. Nature https://doi.org/10.1038/s41586-021-04060-7 (2021). · DOI
  77. Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021). · DOI · Paper page
  78. Wu, K. et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Preprint at bioRxiv https://doi.org/10.1101/2021.04.13.439482 (2021). · DOI · Paper page
  79. Morens, D. M. & Fauci, A. S. Emerging pandemic diseases: how we got to COVID-19. Cell 182, 1077–1092 (2020). · DOI
  80. Heaton, N. S., Sachs, D., Chen, C.-J., Hai, R. & Palese, P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl Acad. Sci. USA 110, 20248–20253 (2013). · DOI
  81. Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432 (2018). · DOI
  82. Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021). · DOI
  83. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015). · DOI
  84. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015). · DOI
  85. Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699–704 (2014). · DOI
  86. Ellebedy, A. H. et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proc. Natl Acad. Sci. USA 117, 17957–17964 (2020). · DOI
  87. Nachbagauer, R. et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88, 13260–13268 (2014). · DOI
  88. Viant, C. et al. Germinal center–dependent and –independent memory B cells produced throughout the immune response. J. Exp. Med. 218, e20202489 (2021). · DOI
  89. Winslow, G. M., Papillion, A. M., Kenderes, K. J. & Levack, R. C. CD11c+T-bet+ memory B cells: immune maintenance during chronic infection and inflammation? Cell Immunol. 321, 8–17 (2017). · DOI
  90. Oliviero, B. et al. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol. Immunol. 17, 1101–1103 (2020). · DOI
  91. Wildner, N. H. et al. B cell analysis in SARS-CoV-2 versus malaria: increased frequencies of plasmablasts and atypical memory B cells in COVID-19. J. Leukoc. Biol. 109, 77–90 (2021). · DOI
  92. Tomayko, M. M., Steinel, N. C., Anderson, S. M. & Shlomchik, M. J. Cutting edge: hierarchy of maturity of murine memory B cell subsets. J. Immunol. 185, 7146–7150 (2010). · DOI
  93. Stamper, C. & Wilson, P. Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. Res. Sq. https://doi.org/10.21203/rs.3.rs-80476/v1 (2010). · DOI
  94. Ogega, C. O. et al. Durable SARS-CoV-2 B cell immunity after mild or severe disease. J. Clin. Invest. 131, e145516 (2021). · DOI
  95. Laidlaw, B. J. & Cyster, J. G. Transcriptional regulation of memory B cell differentiation. Nat. Rev. Immunol. 21, 209–220 (2021). · DOI
  96. He, J.-S. et al. IgG1 memory B cells keep the memory of IgE responses. Nat. Commun. 8, 641 (2017).
  97. Russell, M. W., Moldoveanu, Z., Ogra, P. L. & Mestecky, J. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front. Immunol. 11, 611337 (2020). · DOI
  98. Palladino, G., Mozdzanowska, K., Washko, G. & Gerhard, W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69, 2075–2081 (1995). · DOI
  99. Centers for Disease Control and Prevention. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings — Barnstable County, Massachusetts, July 2021. MMWR 70, 1059–1062 (1995).
  100. Li, B. et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Preprint at medRxiv https://doi.org/10.1101/2021.07.07.21260122 (2021). · DOI
  101. Shamier, M. C. et al. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. Preprint at medRxiv https://doi.org/10.1101/2021.08.20.21262158 (2021). · DOI · Paper page
  102. Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97–108 (2019). · DOI
  103. Allie, S. R. & Randall, T. D. Resident memory B cells. Viral Immunol. 33, 282–293 (2020). · DOI
  104. Weisel, N. M. et al. Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype. Blood 136, 2774–2785 (2020). · DOI
  105. Adachi, Y. et al. Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J. Exp. Med. 212, 1709–1723 (2015). · DOI
  106. Kim, T. S., Hufford, M. M., Sun, J., Fu, Y.-X. & Braciale, T. J. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J. Exp. Med. 207, 1161–1172 (2010). · DOI
  107. Tan, H.-X. et al. Inducible bronchus-associated lymphoid tissues (iBALT) serve as sites of B cell selection and maturation following influenza infection in mice. Front. Immunol. 10, 611 (2019). · DOI
  108. Moyron-Quiroz, J. E. et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643–654 (2006). · DOI
  109. Moyron-Quiroz, J. E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927–934 (2004). · DOI
  110. Onodera, T. et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc. Natl Acad. Sci. USA 109, 2485–2490 (2012). · DOI
  111. GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus–infected mice. J. Exp. Med. 206, 2339–2349 (2009). · DOI
  112. Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169–184.e13 (2020). · DOI
  113. Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021). · DOI
  114. Doremalen, N. V. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, eabh0755 (2021).
  115. Ku, Z. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 595, 718–723 (2021). · DOI
  116. Lavelle, E. C. & Ward, R. W. Mucosal vaccines — fortifying the frontiers. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-021-00583-2 (2021). · DOI
  117. Mades, A. et al. Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination. Preprint at medRxiv https://doi.org/10.1101/2021.05.06.21256403 (2021). · DOI
  118. Ketas, T. J. et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. Pathog. Immun. 6, 116–134 (2021). · DOI
  119. Wisnewski, A. V., Luna, J. C. & Redlich, C. A. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS ONE 16, e0249499 (2021).
  120. Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021). · DOI · Paper page
  121. Corthésy, B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front. Immunol. 4, 185 (2013). · DOI
  122. Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. Iubmb Life 69, 297–304 (2017). · DOI · Paper page
  123. Bergamaschi, L. et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54, 1257–1275.e8 (2021). · DOI
  124. Breton, G. et al. Persistent cellular immunity to SARS-CoV-2 infection. J. Exp. Med. 218, e20202515 (2021). · DOI · Paper page
  125. Painter, M. M. et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination. Immunity https://doi.org/10.1016/j.immuni.2021.08.001 (2021). · DOI · Paper page
  126. Mallajosyula, V. et al. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 6, eabg5669 (2021). · DOI
  127. MacLeod, M. K. L. et al. Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J. Immunol. 186, 2889–2896 (2011). · DOI
  128. Grau-Expósito, J. et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat. Commun. 12, 3010 (2021). · DOI

Cited by

Sorted by citations

See all 268

Metadata

Authors
Laidlaw, B. J., & Ellebedy, A. H.
ORCID
Venue
Nature Reviews Immunology
Publisher
Springer Science and Business Media LLC
Published
2021-12-06
Volume
22
Issue
1
Pages
7-18
ISSN
  • 1474-1733
  • 1474-1741
DOI
10.1038/s41577-021-00657-1
PMC
PMC8647067
Cited by
268
References
62
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review